SECsense Logo

Evaxion Biotech A/S Reports Phase 2 Trial Extension for EVX-01 Vaccine

$EVAX
Form 6-K
Filed on: 2025-02-25
Source
Evaxion Biotech A/S Reports Phase 2 Trial Extension for EVX-01 Vaccine

Here are the key insights extracted from the provided section of the financial report for Evaxion Biotech A/S:

  1. Filing Type: This document is a Form 6-K, which is typically used by foreign private issuers to report information that is required to be made public in their home country.
  2. Filing Date: The report is dated February 25, 2025.
  3. Company Information:
  • Name: Evaxion Biotech A/S
  • Address: Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark
  • Commission File Number: 001-39950
  1. Form Selection: The company indicated that it files annual reports under Form 20-F.
  2. Purpose of Filing: This Form 6-K is intended to provide information related to corporate events or matters relevant to the company.
  3. Press Release: The report includes a press release announcing the extension of a phase 2 trial for the personalized cancer vaccine EVX-01. This decision is aimed at enhancing the clinical data package related to the vaccine.
  4. Incorporation by Reference: This report is to be incorporated by reference into several registration statements filed by the company, which include Forms S-8 and F-1, indicating ongoing capital-raising activities or securities offerings.
  5. Signature: The document is signed by Christian Kanstrup, the Chief Executive Officer of Evaxion Biotech A/S.

This report highlights an important development in the company's clinical trial activities, which may have implications for its future growth and product offerings in the biotech sector. The extension of the trial may enhance the company’s position in the market for cancer vaccines.